Spots Global Cancer Trial Database for Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
Official Title: A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer
Study ID: NCT00606879
Conditions
Interventions
Study Description
Brief Summary: SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Premier Onocology, California, Santa Monica, California, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact Details
Name: Lee Rosen, MD
Affiliation: Premier Onocology, California
Role: PRINCIPAL_INVESTIGATOR
Name: Howard Burris, MD
Affiliation: Sarch Cannon Research Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
